Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyChristine E. Brown, Behnam Badie, Anita Kurien et al.|New England Journal of Medicine|2016Cited by 1.8k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent GlioblastomaChristine E. Brown, Michael C. Jensen, Behnam Badie et al.|Clinical Cancer Research|2015Cited by 754
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastomaLinda M. Liau, Santosh Kesari, Keyoumars Ashkan et al.|Journal of Translational Medicine|2018Cited by 540
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent GlioblastomaLinda M. Liau, Lynne P. Taylor, Keyoumars Ashkan et al.|JAMA Oncology|2022Cited by 411
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastomaLinda M. Liau, Santosh Kesari, Keyoumars Ashkan et al.|Journal of Translational Medicine|2018Cited by 17